for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shenzhen Kangtai Biological Prods Co Ltd

300601.SZ

Latest Trade

130.40CNY

Change

-3.71(-2.77%)

Volume

2,618,267

Today's Range

130.28

 - 

136.00

52 Week Range

120.61

 - 

249.69

As of on the Shenzhen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
134.11
Open
132.81
Volume
2,618,267
3M AVG Volume
148.52
Today's High
136.00
Today's Low
130.28
52 Week High
249.69
52 Week Low
120.61
Shares Out (MIL)
686.37
Market Cap (MIL)
92,049.16
Forward P/E
119.93
Dividend (Yield %)
0.22

Next Event

Q4 2020 Shenzhen Kangtai Biological Products Co Ltd Earnings Release

Latest Developments

More

Kangtai Biological Products' Shareholder Agrees To Sell 1.5% Stake

Shenzhen Kangtai Biological Products Says 9-Month Net Profit Up 0.6% Y/Y

Shenzhen Kangtai Biological Products Sees 2019 Net Profit Up 26.2%-35.4% Y/Y

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shenzhen Kangtai Biological Prods Co Ltd

Shenzhen Kangtai Biological Products Co.,Ltd. is a China-based company and mainly engaged in research and development, manufacture and sale of vaccine. The main products of the company are recombinant hepatitis B virus, haemophilus influenzae type b combined vaccine, measles rubella combined attenuated live vaccine, non-cell Bai Bai Po haemophilus influenzae combined vaccine and other products. The Company operates its businesses primary in domestic market.

Industry

Biotechnology & Drugs

Contact Info

No. 10 Shutianpu Road

Matian Neighborhood, Guangming District

SHENZHEN, GNG

518106

China

+86.755.26988558

http://www.biokangtai.com

Executive Leadership

Weimin Du

Chairman of the Board, President

Haifa Zheng

Vice Chairman of the Board, Vice President

Xiang Miao

Finance Director, Vice President, Secretary of the Board

Jianhui Gan

Vice President

Tong Li

Vice President

Key Stats

1.20 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2017

1.2K

2018

2.0K

2019

1.9K

2020(E)

2.5K
EPS (CNY)

2017

0.354

2018

0.700

2019

0.900

2020(E)

1.138
Price To Earnings (TTM)
152.72
Price To Sales (TTM)
46.74
Price To Book (MRQ)
13.00
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.62
LT Debt To Equity (MRQ)
0.29
Return on Investment (TTM)
11.65
Return on Equity (TTM)
9.50

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up